MX2020014028A - Composición farmacéutica que comprende ilaprazol o una sal de este y método para su preparación. - Google Patents
Composición farmacéutica que comprende ilaprazol o una sal de este y método para su preparación.Info
- Publication number
- MX2020014028A MX2020014028A MX2020014028A MX2020014028A MX2020014028A MX 2020014028 A MX2020014028 A MX 2020014028A MX 2020014028 A MX2020014028 A MX 2020014028A MX 2020014028 A MX2020014028 A MX 2020014028A MX 2020014028 A MX2020014028 A MX 2020014028A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- ilaprazole
- salt
- preparation
- method therefor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que contiene ilaprazol o una sal de este compuesto, así como un método para su preparación. La composición farmacéutica contiene o consiste en ilaprazol o una sal de este compuesto y un derivado de ilaprazol, en donde la cantidad del derivado de ilaprazol en la composición farmacéutica no supera el 1.3% en peso (es menor o igual a 1.3% en peso). La composición se puede utilizar para el tratamiento de hemorragia por ulceras pépticas, ulceras por estrés y para la prevención de hemorragias gastrointestinales superiores provocadas por enfermedades graves.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810652046.XA CN108685918B (zh) | 2018-06-22 | 2018-06-22 | 一种含艾普拉唑或其盐的药物组合物及其制备方法 |
PCT/CN2018/111611 WO2019242181A1 (zh) | 2018-06-22 | 2018-10-24 | 一种含艾普拉唑或其盐的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020014028A true MX2020014028A (es) | 2021-04-28 |
Family
ID=63849057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020014028A MX2020014028A (es) | 2018-06-22 | 2018-10-24 | Composición farmacéutica que comprende ilaprazol o una sal de este y método para su preparación. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210260046A1 (es) |
EP (1) | EP3811941B1 (es) |
JP (1) | JP7250920B2 (es) |
CN (1) | CN108685918B (es) |
BR (1) | BR112020026264A2 (es) |
ES (1) | ES2969740T3 (es) |
MX (1) | MX2020014028A (es) |
PH (1) | PH12020552230A1 (es) |
PL (1) | PL3811941T3 (es) |
WO (1) | WO2019242181A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108685918B (zh) * | 2018-06-22 | 2021-02-09 | 丽珠医药集团股份有限公司 | 一种含艾普拉唑或其盐的药物组合物及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0179401B1 (ko) * | 1994-02-28 | 1999-03-20 | 송택선 | 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체 |
CN1184970C (zh) | 2002-01-24 | 2005-01-19 | 一洋药品株式会社 | 含有2-[(4-甲氧基-3-甲基)-2-吡啶基]甲基亚磺酰基-5-(1h-吡咯-1-基)-1h-苯并咪唑的口服片剂 |
CN1225240C (zh) | 2002-03-01 | 2005-11-02 | 一洋药品株式会社 | 含有2-[(4-甲氧基-3-甲基)-2-吡啶基]甲基亚磺酰基-5-(1h-吡咯-1-基)-1h-苯并咪唑的肠溶包衣微粒制剂 |
CZ2009417A3 (cs) * | 2009-06-30 | 2011-01-12 | Zentiva, K.S. | Nový zpusob výroby 2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-6-(1H-pyrrol-1-yl) 1H-benzimidazolu (ilaprazolu) |
CN102038648B (zh) | 2009-10-23 | 2012-07-25 | 丽珠医药集团股份有限公司 | 治疗消化性溃疡的粉针剂及其制备方法 |
CN105055342A (zh) | 2015-08-13 | 2015-11-18 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗消化性溃疡的药物艾普拉唑钠组合物冻干粉针剂 |
CN105769777B (zh) * | 2016-04-02 | 2018-08-10 | 丽珠医药集团股份有限公司 | 一种艾普拉唑钠冻干粉针剂 |
CN105769778B (zh) | 2016-04-02 | 2018-08-10 | 丽珠医药集团股份有限公司 | 一种艾普拉唑钠粉针剂及其制备方法 |
CN108685918B (zh) * | 2018-06-22 | 2021-02-09 | 丽珠医药集团股份有限公司 | 一种含艾普拉唑或其盐的药物组合物及其制备方法 |
-
2018
- 2018-06-22 CN CN201810652046.XA patent/CN108685918B/zh active Active
- 2018-10-24 BR BR112020026264-1A patent/BR112020026264A2/pt unknown
- 2018-10-24 MX MX2020014028A patent/MX2020014028A/es unknown
- 2018-10-24 PL PL18923679.7T patent/PL3811941T3/pl unknown
- 2018-10-24 JP JP2021520259A patent/JP7250920B2/ja active Active
- 2018-10-24 EP EP18923679.7A patent/EP3811941B1/en active Active
- 2018-10-24 WO PCT/CN2018/111611 patent/WO2019242181A1/zh active Application Filing
- 2018-10-24 US US17/254,830 patent/US20210260046A1/en active Pending
- 2018-10-24 ES ES18923679T patent/ES2969740T3/es active Active
-
2020
- 2020-12-21 PH PH12020552230A patent/PH12020552230A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3811941A4 (en) | 2022-04-13 |
EP3811941B1 (en) | 2023-11-29 |
PL3811941T3 (pl) | 2024-05-06 |
JP2021527716A (ja) | 2021-10-14 |
BR112020026264A2 (pt) | 2021-03-30 |
CN108685918A (zh) | 2018-10-23 |
ES2969740T3 (es) | 2024-05-22 |
CN108685918B (zh) | 2021-02-09 |
EP3811941A1 (en) | 2021-04-28 |
PH12020552230A1 (en) | 2021-06-28 |
JP7250920B2 (ja) | 2023-04-03 |
EP3811941C0 (en) | 2023-11-29 |
WO2019242181A1 (zh) | 2019-12-26 |
US20210260046A1 (en) | 2021-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019009861A (es) | Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas. | |
MX2014013924A (es) | Proceso para la preparacion de n- [5- (3,5-difluoro-bencil) -1h-indazol-3-il] -4- (4-metil-piperazin-1-il) -2- (tetrahidro-piran-4-ilamino) -benzamida. | |
WO2018226622A8 (en) | Compounds for treating huntington's disease | |
MX2018007022A (es) | Metodos para tratar la enfermedad de huntington. | |
MX2021006283A (es) | Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos. | |
EA201792548A1 (ru) | 4-гидрокси-3-(гетероарил)пиридин-2-оновые агонисты apj для применения в лечении сердечно-сосудистых заболеваний | |
SA519402180B1 (ar) | مركب حلقي غير متجانس جديد، وطريقة تحضيره، وتركيبة صيدلانية تشتمل على نفس المركب | |
MX2020002399A (es) | Inhibidores del enlace proteína-proteína de wdr5. | |
MX2018014298A (es) | Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida. | |
PH12021550027A1 (en) | Substituted thiophenecarboxamides and analogues as antibacterials agents | |
PH12021551280A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
MX2021002323A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
PH12020551035A1 (en) | Novel anthranilamides, their use as insecticide and processes for preparing the same | |
PH12020552230A1 (en) | Pharmaceutical composition comprising ilaprazole or salt thereof and preparation method theref or | |
SA520411726B1 (ar) | مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه | |
TN2021000079A1 (en) | Ceramic paste compositions for 3d printing | |
MX2021014864A (es) | N-(pirid-3-il)carboxamidas fungicidas. | |
MY171509A (en) | Toothpaste composition | |
MX2019012967A (es) | Cristal de base libre de derivados benzofurano y metodo de preparacion. | |
MY192720A (en) | Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same | |
MX2021006490A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
MX2020012609A (es) | Inhibidor del hif-1?, metodo de preparacion del mismo, y composicion farmaceutica para prevenir o tratar la enfermedad ocular asociada a la angiogenesis, que contiene el mismo como ingrediente activo. | |
MX2020008357A (es) | Piridincarboxamidas novedosas. | |
MX2023000198A (es) | Inhibidores de atr y usos de estos. | |
MX2022009851A (es) | Compuestos útiles para inhibir la cetohexocinasa y métodos para elaborarlos y utilizarlos. |